Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

Back to Details
This page shows the publications co-authored by Donna Neuberg and Jerome Ritz.
Donna Neuberg
Connection Strength
1.782
Jerome Ritz
  1. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
    View in: PubMed
    Score: 0.075
  2. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
    View in: PubMed
    Score: 0.069
  3. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
    View in: PubMed
    Score: 0.068
  4. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
    View in: PubMed
    Score: 0.063
  5. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10; 137(23):3212-3217.
    View in: PubMed
    Score: 0.062
  6. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
    View in: PubMed
    Score: 0.059
  7. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
    View in: PubMed
    Score: 0.059
  8. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.058
  9. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32.
    View in: PubMed
    Score: 0.057
  10. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
    View in: PubMed
    Score: 0.056
  11. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
    View in: PubMed
    Score: 0.052
  12. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
    View in: PubMed
    Score: 0.052
  13. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998 Aug 01; 102(3):561-75.
    View in: PubMed
    Score: 0.051
  14. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
    View in: PubMed
    Score: 0.050
  15. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80.
    View in: PubMed
    Score: 0.050
  16. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
    View in: PubMed
    Score: 0.050
  17. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997 Aug 15; 100(4):855-66.
    View in: PubMed
    Score: 0.048
  18. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.047
  19. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
    View in: PubMed
    Score: 0.046
  20. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.044
  21. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.043
  22. Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
    View in: PubMed
    Score: 0.040
  23. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
    View in: PubMed
    Score: 0.039
  24. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
    View in: PubMed
    Score: 0.038
  25. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
    View in: PubMed
    Score: 0.036
  26. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
    View in: PubMed
    Score: 0.035
  27. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
    View in: PubMed
    Score: 0.034
  28. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
    View in: PubMed
    Score: 0.032
  29. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
    View in: PubMed
    Score: 0.031
  30. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956.
    View in: PubMed
    Score: 0.030
  31. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
    View in: PubMed
    Score: 0.028
  32. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
    View in: PubMed
    Score: 0.028
  33. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
    View in: PubMed
    Score: 0.026
  34. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
    View in: PubMed
    Score: 0.025
  35. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
    View in: PubMed
    Score: 0.025
  36. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
    View in: PubMed
    Score: 0.021
  37. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.
    View in: PubMed
    Score: 0.017
  38. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
    View in: PubMed
    Score: 0.016
  39. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44.
    View in: PubMed
    Score: 0.016
  40. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
    View in: PubMed
    Score: 0.014
  41. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
    View in: PubMed
    Score: 0.014
  42. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.
    View in: PubMed
    Score: 0.013
  43. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
    View in: PubMed
    Score: 0.012
  44. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
    View in: PubMed
    Score: 0.012
  45. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
    View in: PubMed
    Score: 0.011
  46. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
    View in: PubMed
    Score: 0.011
  47. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35.
    View in: PubMed
    Score: 0.011
  48. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9.
    View in: PubMed
    Score: 0.008
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.